Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
Gilead agreed to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from privately held PepStar Therapeutics for $1.275 billion in upfront cash. HCXT-2001 is a Phase 1 oral macrocyclic peptide IL-23R inhibitor with an extended half-life, targeting inflammatory bowel disease with potential applications in psoriasis, and could be used alone or in combination with Gilead's emvistegrast. The deal gives Gilead worldwide rights and is expected to close in Q4 2026, but will reduce Gilead's GAAP and non-GAAP EPS by roughly $0.79-$0.83 in the fourth quarter.
Key figures
- Drug Name
- HCXT-2001
- Guidance
- Transaction expected to reduce GAAP and non-GAAP EPS by approximately $0.79 to $0.83 in Q4 2026; deal expected to close in Q4 2026
- Deal Value Usd
- 1275000000
- Phase Of Trial
- Phase 1
- Expected close
- Q4 2026
- Eps impact q4 2026
- $0.79-$0.83 reduction
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.